



HAL
open science

New once daily formulation for trospium in overactive bladder

Christopher Chapple

► **To cite this version:**

Christopher Chapple. New once daily formulation for trospium in overactive bladder. International Journal of Clinical Practice, 2010, 64 (11), pp.1535. 10.1111/j.1742-1241.2010.02493.x. hal-00576628

HAL Id: hal-00576628

<https://hal.science/hal-00576628>

Submitted on 15 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



New once daily formulation for tiroprium in overactive bladder

Journal:	<i>International Journal of Clinical Practice</i>
Manuscript ID:	IJCP-07-10-0370.FT10.R1
Wiley - Manuscript type:	Systematic Review
Date Submitted by the Author:	26-Jul-2010
Complete List of Authors:	Chapple, Christopher; The Royal Hallamshire Hospital, Department of Urology
Specialty area:	

SCHOLARONE™
Manuscripts

22/07/2010

1
2
3 **New once daily formulation for trospium in overactive bladder**
4

5
6 C. Chapple
7

8 Royal Hallamshire Hospital, Sheffield, UK
9

10
11
12
13 Tel: +44 (0)114 271 3048
14

15 Fax: +44 (0)114 2797841
16

17 Email: c.r.chapple@shef.ac.uk
18
19

20
21
22 Correspondence to:
23

24 Professor Christopher Chapple
25

26 Urology Department
27

28 Royal Hallamshire Hospital
29

30 Glossop Road
31

32 Sheffield, S10 2JF
33

34 UK
35
36

37
38 **Disclosure**
39

40 Christopher Chapple is a scientific consultant and/or researcher with Allergan,
41

42 Astellas, Novartis, Ono, Xention, Pfizer and Speciality European Pharma.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22/07/2010

Summary

Aims

To examine the relative efficacy and safety of trospium 20mg bid and 60 mg extended release formulations and position this drug against other antimuscarinic agents

Methods

Data were identified on the pharmacology and pharmacokinetics of trospium chloride. Key publications on trospium 20 mg and 60 mg clinical studies in patients with overactive bladder (OAB) were identified and efficacy and safety compared between these formulations as well as other antimuscarinic agents.

Results

Trospium offers the principal advantage over other antimuscarinic agents that, as it is a quaternary amine, it does not cross the blood-brain barrier and is therefore less likely to cause central nervous system effects observed with several other agents. Moreover, with its minimal liver metabolism, independent of the main cytochrome pathways, trospium has a low risk of drug-drug interaction in patients taking multiple pharmacological agents. Trospium 60 mg ER is as effective as trospium 20 mg bid in improving the key outcome parameters associated with OAB, but with a lower rate of dry mouth, the most common side-effect of these agents. Trospium has comparable efficacy and safety to the other antimuscarinic agents currently marketed. Good patient persistence with treatment has been reported with trospium.

Conclusion

There are currently a large number of antimuscarinic drugs on the market without clear evidence to distinguish one agent from another in terms of efficacy provided an adequate dose is used in the clinical setting. The new formulation of trospium is

22/07/2010

1
2
3 certainly worth considering as a pharmacological treatment of patients with OAB,
4
5 particularly the elderly where one wants to avoid the potential for cognitive
6
7 dysfunction.
8
9

10 11 12 **Review Criteria**

13
14
15 *'How did you gather, select and analyze the info you considered in your review?'*

16
17 A medline search was conducted using the key words trospium and incontinence.
18
19 Data on all other antimuscarinic agents were based on a comprehensive meta-
20
21 analysis as well as medline searches on specific adverse events, e.g. cognitive
22
23 function.
24
25

26 27 **Message for the clinic**

28
29 *'What is the take-home message for the clinician?'* Trospium chloride 60 mg ER can
30
31 be considered a potential addition to the treatment armamentarium for patients with
32
33 overactive bladder, as it brings with the potential of not crossing the blood brain
34
35 barrier because of its underlying physico-chemical structure. Further experience is
36
37 necessary, however, in real life clinical practice as well as results of further controlled
38
39 studies before more definitive conclusions can be drawn.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22/07/2010

Introduction

Overactive bladder (OAB) has been defined by International Continence Society (ICS) as a symptom syndrome comprising “urgency with or without urgency incontinence, usually with frequency and nocturia” (1). The condition is common and one in six adults is reported as having symptoms of OAB (2). The primary therapies for this condition are non-surgical comprising bladder training, biofeedback, medication and a combination of these options, while the first-line medical therapy for OAB relies on antimuscarinic agents (3). By blocking the muscarinic M3 receptors, these reduce the symptoms of OAB in part by a direct action on the detrusor muscle (4) as well as potentially affecting the sensory components of the micturition reflex. The widespread occurrence of muscarinic receptors throughout the body, including the central nervous system, eyes, salivary glands, and gastrointestinal tract, however, means that antimuscarinic therapy is associated with a range of adverse effects (AEs). A number of different formulations are available for the various antimuscarinic agents that are currently available. In the past, one such agent, trospium chloride, has been disadvantaged by not being available as a once a day formulation, but this situation has now been resolved by a new 60 mg extended release (ER) formulation. This review examines the background to this compound and draws comparison between the new formulation and the original twice daily preparation, as well as the existing antimuscarinic agents.

Trospium chloride

Pharmacology

Trospium chloride is an antimuscarinic agent indicated for the symptomatic treatment of urgency incontinence and/or increased urinary frequency and urgency

22/07/2010

1
2
3 as may occur in patients with OAB. It is available in two formulations: a 20 mg IR
4 (immediate release) tablet that is taken twice daily or the more recent 60 mg ER
5 (extended release) tablet that is taken twice daily or the more recent 60 mg ER
6 (extended release) capsule (Regurin XL[®]; Urivesc[®]; Sanctura[®] XR) for once daily
7 administration. The twice daily formulation is widely available worldwide, while the
8 extended release formulation is currently approved in most EU Countries as well as
9 in the USA and Canada. Trospium is a quaternary amine that has low lipophilicity
10 and is charged at neutral pH (5). Following oral administration, it is absorbed rather
11 slowly, with peak plasma levels reached at 4.5 hours and at 5.0 hours with the IR
12 and ER formulations, respectively (6); no first-pass effect for systemically absorbed
13 trospium has been observed (7,8). Up to 80% of trospium is excreted unchanged in
14 the urine and metabolism by the cytochrome P450 pathway does not occur (8,9),
15 suggesting that no metabolic interactions with other drugs are likely (8).

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 Antimuscarinic agents interact with muscarinic receptors throughout the body,
33 of which the five known receptor subtypes are all expressed in the central nervous
34 system (CNS) (10). Interactions with the M₁, M₂, and M₄ subtypes have each been
35 implicated in cognitive impairment and the M₁ receptor subtype is particularly
36 relevant in this regard (10,11). In order to be active within the brain, the individual
37 agent has to cross the blood-brain barrier, either through active transport or passive
38 penetration; the latter is more likely with small hydrophilic molecules. Drugs such as
39 oxybutinin (357 kDA) can readily cross the blood-brain barrier and their subsequent
40 negative effects on cognitive function have been documented (12). In contrast, data
41 indicate that trospium was less likely to produce CNS AEs than oxybutinin due to its
42 inability to cross the blood brain barrier (13). Research also suggests that trospium
43 affects general and traffic safety performance to a lesser extent than oxybutinin,
44 tolterodine and propiverine (14). Further support for the lack of CNS AEs comes from
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22/07/2010

1
2
3 a study by Staskin and Harnett, which showed that trospium did not increase
4
5 daytime sleepiness or reduce patient alertness (15). These findings are particularly
6
7 relevant for the elderly who have cerebrovascular disease or other co-morbidities
8
9 that alter the permeability of the blood-brain barrier who might be a greater risk of a
10
11 CNS adverse event.
12
13

14 15 16 17 *Efficacy*

18
19 No head to head studies have been conducted on trospium 20 mg immediate
20
21 release and the 60 mg ER formulations. Considering the outcomes from individual
22
23 studies (Table 1) (16–19), three key outcome parameters are reported, i.e. reduction
24
25 in daily incontinence episode rate, daily micturition rate and daily urgency episodes,
26
27 which show significant improvements with both dosages of trospium over placebo.
28
29 No distinction can be observed between the two dosage forms for any of these
30
31 parameters, albeit, the duration of treatment is longer in one of the lower dosage
32
33 studies. This latter study actually reports the longest term outcome for trospium 20
34
35 mg bid and at 1 year confirms the durability of the therapy.
36
37
38
39

40
41 Additional data on the efficacy of trospium 20 mg bid dosage come from a 3-
42
43 week randomized placebo controlled study of 208 patients with detrusor overactivity
44
45 (20). Efficacy was based on urodynamic assessments including maximum
46
47 cystometric bladder capacity, volume at first overactive and maximum contraction,
48
49 detrusor pressures at different bladder states. Results showed that trospium
50
51 produced significant improvements in a number of urodynamic parameters (Table 2).
52
53 In addition, most patients treated with trospium rated the acceptability of study
54
55 medication as good or very good; 50% and 37%, respectively compared with 40%
56
57 and 29%, respectively, with placebo.
58
59
60

22/07/2010

1
2
3 The pivotal randomized controlled trials on trospium 60 mg ER formulation
4 were conducted in the US and involved over 1000 patients at over 100 sites (18,19).
5
6 The study by Staskin et al indicated that in addition to the primary efficacy variables
7 shown in Table 2, twice as many patients treated with trospium achieved
8 normalization (no urinary urgency episodes and a daily void frequency of ≤ 8)
9 compared with placebo (20.5% vs. 11.3%; $p < 0.01$) (18). There were also significant
10 improvements in other secondary outcome measures (urgency urinary incontinence
11 [UUI] episodes per week, urgency severity associated with toilet voids, volume
12 voided per void, daily frequency of urgency-associated voids and OAB-SCS). The
13 time to onset of clinical benefit was superior for trospium compared with placebo,
14 with benefits being observed in week 1 of the 12-week study for several of the
15 primary and secondary outcomes. In the Dmochowski et al study, from week 1
16 significantly more patients were dry in the trospium group than in the placebo group
17 and at week 12 this rose to 36% and 21%, respectively ($P < 0.001$) (19). Similarly,
18 significantly more patients treated with trospium were normalized from week 4 and at
19 week 12, 21% vs. 11% were normalized in the trospium and placebo groups,
20 respectively ($P < 0.01$).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 A *post hoc* analysis was conducted on pooled data from the two US 12-week,
44 studies (21). Patients were stratified by the mean number of UUI episodes/day at
45 baseline (1.0, > 1.0–2.0, > 2.0–5.0 or > 5.0). Results showed that baseline UUI
46 levels were inversely correlated with the week 12 percentage of patients continent
47 and that more patients were continent with trospium compared with placebo at all
48 degrees of severity. Complete continence was achieved in 75% of trospium
49 recipients with 1.0 UUI/day at baseline and 48% of those with > 1.0–2.0 UUIs/day
50 at baseline indicating that patients with less severe OAB could anticipate higher 'dry
51
52
53
54
55
56
57
58
59
60

22/07/2010

1
2
3 rates' following treatment. A further *post-hoc* analysis on the two studies examined
4 the effects of obesity on outcome. Increased body mass index has been shown to
5 be associated with severity of OAB in a number of studies in both men and women
6 (22,23). The analysis showed that trospium was more effective than placebo at
7 reducing the primary endpoints (number of daily voids and UUI; $P < 0.0001$) and at
8 improving the secondary end-points (percent patients continent and urgency
9 severity; $P < 0.0001$) for WHO obesity levels I and II.
10
11
12
13
14
15
16
17
18
19
20
21

22 Safety

23 Comparison is made in Table 3 of the most frequent AEs reported with the two
24 formulations of trospium (16–19). This shows a lower rate of AEs with the 60 mg ER
25 dose than the 20 mg bid. There was a marked decrease in the incidence of dry
26 mouth with trospium ER; the rates reported for the 20 mg and 60 mg formulations
27 were 21–33% and 8.7–12.9%, respectively. Improved formulations and extended
28 release delivery systems developed for other antimuscarinic drugs have
29 demonstrated an improved therapeutic index, namely by maintaining efficacy but
30 improving the safety profile (24). This is combined with a significantly better
31 improvement in mean number of urgency incontinence episodes per week with the
32 ER formulation. The lower rate of AE has indeed been suggested to be related to the
33 pharmacokinetic profile of this novel formulation; in particular, the systemic exposure
34 to trospium at steady state is lower following administration of the ER formulation, as
35 compared with the IR one, possibly by reducing the chance of reaching the threshold
36 serum level at which AEs occur (6).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 A recent open label, non comparative, evaluation study of 12 healthy volunteers,
58 insinuated the ability of trospium extended release to penetrate the blood brain
59
60

22/07/2010

1
2
3 barrier. This looked at serum plasma levels as well as levels in the cerebral spinal
4
5 fluid at up to 24 hours post dose, when a steady state had been reached at 10 days
6
7 after starting dosing. All of the volunteers were aged 65-75. No clinically meaningful
8
9 drug effect was seen after neuro-cognitive measurement and trospium chloride was
10
11 undetectable to multiple time points in these patients. The study concluded that
12
13 pharmacological and behavioural results supported a lack of CNS penetration in
14
15 potentially neuro-cognitively vulnerable elderly people (25).
16
17
18
19
20
21

22 *Comparison to other antimuscarinic agents*

23
24
25 A meta-analysis was conducted in 2008 on the safety and efficacy of antimuscarinic
26
27 agents for OAB, which involved an analysis of published randomized controlled trials
28
29 on drug dosages that were licensed for use in Europe (26). The cutpoint for
30
31 publication was 18 October 2007. Comparison can now be made to the two RCTs on
32
33 trospium 60 mg ER that have subsequently been published, namely the studies by
34
35 Staskin et al (18) and Dmochowski et al. (19). The meta-analysis reported pooled
36
37 differences in mean change in incontinence episodes of 0.4 to 1.1 episodes per day.
38
39 The data on trospium compares favourably with this at 0.5–2.4. Pooled differences
40
41 for mean change in number of micturitions per day ranged from 0.5 to 1.3 episodes
42
43 in the meta-analysis compared with 0.3 to 7.9 in the trospium studies. With regard to
44
45 urgency episodes per day, the trospium studies show a change in rate of 0.3 to 6.7
46
47 compared with 0.64 to 1.56 episodes per day in the meta-analysis. These findings
48
49 suggest that trospium at both dosage forms is as effective as the other
50
51 antimuscarinic agents available. The safety of trospium is comparable to the other
52
53 antimuscarinic agents reported in the meta-analysis with the exception of dry mouth
54
55
56
57
58
59
60

22/07/2010

1
2
3 where the 8.7% incidence (placebo 3.0%) with the 60 mg ER dosage (18) was the
4
5 lowest reported for any oral antimuscarinics.
6
7

8
9 The efficacy of the antimuscarinics has to be balanced against the side-
10 effects observed and patient tolerability of these effects. Persistence rates with the
11 different antimuscarinic vary between rates reported in long-term clinical trials and
12 real life situations. Very good long-term persistence has been reported for several
13 antimuscarinic agents including, 75% for trospium at 12 months (16), 81% for
14 solifenacin at 40 weeks (27), 71% for tolterodine at 1 year (28) and 66% for
15 darifenacin at 2 years (29). In contrast, a much lower rate of 44% has been reported
16 for real-life prescription renewal for tolterodine ER after 30 days and this reduced to
17 9% at 1 year (30). A more recent report has examined the persistence of
18 antimuscarinics based on a Danish database of reimbursed prescriptions in 2006 in
19 a sample of the population representative of the country as a whole (31). Results
20 showed that apart from trospium, all drugs had continuation rates of less than 50% at
21 6 months, less than 25% at 1 year and less than 10% at 2 years and longer (Fig. 1).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 The continuation rates for trospium were 46%, 36%, 22% and 16% at 6
41 months, 1, 2 and 3 years, respectively. The authors speculated that the higher
42 persistence rates seen with trospium might be due to its lack of interaction with
43 concomitant medications, making it a safer option particularly in the elderly. Factors
44 affecting discontinuation likelihood were gender (men > women), age (young > old),
45 dose (high > low) and previous experience with OAB drugs.
46
47
48
49
50
51
52
53
54

55 **Conclusion**

56
57 There are currently a large number of antimuscarinic drugs on the market with little
58 clear evidence to distinguish one agent from another in terms of efficacy provided an
59
60

22/07/2010

1
2
3 adequate dose is used in the clinical setting. In particular, this is due to the paucity of
4
5 head to head clinical studies. The principal difference between compounds relates to
6
7 pharmacological and pharmacokinetic factors. Another important aspect is ease of
8
9 administration and the once daily formulations clearly provide additional patient
10
11 benefit. Trospium, now available as a new once daily formulation, has the added
12
13 advantage that it does not cross the blood brain barrier, so it may well be beneficial
14
15 in elderly patients who are at higher risk of potential effects on the CNS. It is
16
17 unclear as to whether direct excretion of trospium in the urine is relevant to its clinical
18
19 use, but this certainly may be important in its profile of action. Indeed, it has been
20
21 suggested (18,19) that the relative accumulation of active drug in urine, and its
22
23 consequent anticholinergic effect exerted on the urothelium (32) , may improve the
24
25 control of urgency. Future work should include further controlled studies, possibly
26
27 head-to-head comparisons with other once daily antimuscarinics, in order to provide
28
29 additional insights into the relative benefits of alternative treatment options.
30
31
32
33
34
35
36
37
38
39
40

41 **Figure legend**

42
43 **Figure 1.** Kaplan-Meier plots of persistence with antimuscarinic drugs for the
44
45 treatment of overactive bladder. Data expressed as proportion of treatment episodes
46
47 over time. With kind permission from Springerlink, Eur J Clin Pharmacol, Persistence
48
49 with antimuscarinic drug use, 65(3), 2008, 312, Brostrom S, Hallas J, Fig. 1.
50
51
52
53
54
55
56
57
58
59
60

22/07/2010

References

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neuourol Urodyn* 2002; **21**: 167–78.
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int* 2001; **87**: 760–6.
3. Ouslander JG. Management of overactive bladder. *N Engl J Med* 2004; **350**: 786–98.
4. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. *J Auton Pharmacol* 2001; **21**: 243–8.
5. Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. *Urol Clin North Am.* 2006; **33**: 465–73.
6. Silver N, Sandage B, Sabounjian L, Schwiderski U, Shipley J and Harnett M. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice daily trospium chloride 20 mg in healthy adults. *J. Clin. Pharmacol* 2010 Feb, **50(2)**: 143-50
7. Sandage B, Najarian N, Lasseter K. The effect of hepatic disease on the pharmacokinetics of trospium chloride. Poster Presentation ICS and IUGA Joint Meeting Paris 2004. Abstract 584.
8. Trospium chloride PI.

22/07/2010

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9. Schladitz-Keil G, Spahn H, Mutschler E. Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. *Arzneimittelforschung* 1986; **36**: 984–7.
 10. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol* 2006; **148**: 565–78.
 11. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. *J Am Geriatr Soc* 2005; **53**: 2195–201.
 12. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. *Int J Clin Pract* 2008; **62**: 1792–800.
 13. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. *Eur J Clin Pharmacol* 1994; **47**: 337–43.
 14. Herberg KW. General and traffic safety and the effects of incontinence medication: new studies on the safety potential of urological anticholinergics. *Med Welt* 1999; **50**: 217–22.
 15. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. *Curr Urol Rep* 2004; **5**: 423–6.
 16. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. *World J Urol* 2003; **20(6)**: 392–9.

22/07/2010

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. *J Urol* 2004; **171**: 2311–5.
18. Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase three trial. *J Urol* 2007; **178**: 978–84.
19. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. *Urology* 2008; **71**: 449–54.
20. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. *BJU Int* 2000; **85**: 659–64.
21. Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. *Int J Clin Pract* 2009; **63**: 973–6.
22. Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: A longitudinal study in women. *BJU Int* 2003; **92**: 69–77.
23. Dallosso HM, Matthews RJ, McGrother CW, et al. The association of diet and other lifestyle factors with the onset of overactive bladder: A longitudinal study in men. *Public Health Nutr* 2004; **7**: 885–91.
24. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. *Urology* 2001; **57**: 414–21.

22/07/2010

- 1
2
3
4 25. Staskin D, Kay G, Goldman HB, Ling J, Bashi K, Oefelein MG. Sanctura XR a
5 muscarinic antagonist resists transport (SMART) across the blood-brain
6 barrier (BBB): A prospective, neurocognitive, biodistribution and
7
8 pharmacokinetic study of extended release trospium chloride (TrCl). *JUrol*
9
10 2010; **183**: 4: Supplement, Abstract 1501
11
12
13
14
15 26. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The
16 effects of antimuscarinic treatments in overactive bladder: an update of a
17
18 systematic review and meta-analysis. *Eur Urol* 2008; **54**: 543–62.
19
20
21
22 27. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin
23 treatment associated with persistence with therapy in patients with overactive
24
25 bladder syndrome. *Eur Urol* 2005; **47**: 376–84.
26
27
28
29 28. Kreder K, Mayne C, Jonas U. Long term safety, tolerability and efficacy of
30 extended-release tolterodine in the treatment of overactive bladder. *Eur Urol*
31
32 2002; **41**: 588–95.
33
34
35
36 29. Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for
37 overactive bladder: results of a 2-year, open-label extension study. *BJU Int*
38
39 2006; **98**: 1025–32.
40
41
42
43 30. Shay FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with
44 overactive bladder pharmacotherapy in a Medicaid population. *Am J Managed*
45
46 *Care* 2005; **11**: S121–9.
47
48
49
50 31. Brostrom S, Hallas J. Persistence with antimuscarinic drug use. *Eur J Clin*
51
52 *Pharmacol* 2008; **65**: 309–14.
53
54
55 32. Kim, Y, Yoshimura N, Masuda H, de Miguel F and Chancellor M. Intravesical
56 instillation of human urine after oral administration of trospium, tolterodine and
57
58 oxybutynin in a rat model of detrusor overactivity. *BJU int* 2005, **97**: 400-3
59
60

22/07/2010

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table 1 Efficacy of trospium chloride compared with placebo; results shown represent change from mean baseline values at 12 weeks except where indicated

Study	Dosage	No. patients	Incontinence episodes/day	Micturition/day	Urgency episodes/day
Halaska et al. 2003 (16)	20 mg bid TC ¹	267	-0.5	-7.9	-6.7
Zinner et al. 2004 (17)	20 mg bid TC	256	-2.3 ^a	-0.3 ^a	-0.3 ^a
	Placebo	256	-1.9	-0.2	-0.1
Staskin et al. 2007 (18)	60 mg ER TC	292	-2.48 ^c	-2.81 ^b	-3.11 ^b
	Placebo	300	-1.93	-1.99	-2.12
Dmochowski et al. 2008 (19)	60 mg ER TC	267	-2.4 ^d	-2.5 ^e	-
	Placebo	276	-1.6	-1.8	-

¹At week 52

Comparison to placebo: ^aP ≤ 0.0001; ^bP < 0.0001; ^cP = 0.0022; ^dP < 0.001; ^eP ≤ 0.001

Table 2 Improvement in urodynamic parameters with trosipium 20 mg bid

Parameter	Mean treatment effect compared with placebo	P value
Max cystometric bladder capacity (ml)	+37.3	0.0054
Vol at first unstable contraction (ml)	+63.6	0.0015
Vol at max contraction (ml)	+29.2	0.0113
Bladder compliance (ml/cmH ₂ O)	-1.2	0.1072
Residual urine (ml)	+5.5	0.0285
Max detrusor pressure at first unstable contraction (cmH ₂ O)	-5.2	0.1278

Table 3 Treatment emergent adverse events (AEs) at least possibly related to study medication. Data shown are number of events (%)

AE	Halaska et al. 2003 (16)	Zinner et al 2004 ¹ (17)		Staskin et al 2007 ² (18)		Dmochowski et al. 2008 (19)	
	Trospium 20 mg bid	Placebo	Trospium 20 mg bid	Placebo	Trospium 60 mg ER	Placebo	Trospium 60 mg ER
Gastrointestinal							
Dry mouth	87 (33%)	17 (6.5%)	57 (21.8%)	9 (3.0%)	26 (8.7%)	13 (4.6%)	36 (12.9%)
Constipation	18 (7%)	10 (3.8%)	25 (9.5%)	4 (1.3%)	28 (9.4%)	5 (1.8%)	13 (4.6%)
Abdominal pain	5 (2%)	3 (1.1%)	8 (3.1%)	2 (0.7%)	3 (1.0%)	–	–
Lower abdominal pain	–	–	–	3 (1.0%)	3 (1.0%)	–	–
Abdominal distension	–	–	–	1 (0.3%)	3 (1.0%)	–	–
Constipation aggravated	–	–	–	3 (1.0%)	3 (1.0%)	–	–
Nausea	6 (2%)	–	–	2 (0.7%)	3 (1.0%)	–	–
Dyspepsia	13 (5%)	–	–	3 (1.0%)	6 (2.0%)	–	–
Diarrhoea	2 (1%)	14 (5.4%)	8 (3.1%)	–	–	–	–
Dysphagia	9 (3%)	–	–	–	–	–	–
Nervous system							

Headache	11 (4%)	12 (4.6%)	17 (6.5%)	8 (2.6%)	3 (1.0%)	–	–
Blurred vision	9 (3%)	–	–	2 (0.7%)	3 (1.0%)	–	–
Renal							
UTI	33 (12%)	–	–	3 (1.0%)	6 (2.0%)	–	–
Urinary retention	–	–	–	1 (0.3%)	4 (1.3%)	–	–
Other							
Dry eye	–	–	–	1 (0.3%)	4 (1.3%)	–	–
Sleeplessness	10 (4%)	–	–	–	–	–	–

¹Events with $\geq 3\%$ incidence ; ² Events with $\geq 1\%$ incidence

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

